BLA 761121 · Genentech
Polivy
Polatuzumab Vedotin-Piiq · Intravenous
NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanLast checked: Nov 20, 2026Latest source record: Mar 18, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2019
Jun 10, 2019
Approved uses
2
Original approval plus efficacy supplements
Registered trials
107
10 Phase 3, 37 recruiting
FAERS reports
10,202
9,659 serious, 2,154 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Aug 24, 2026.
POLIVY is a CD79b-directed antibody and microtubule inhibitor conjugate indicated: in combination with a rituximab product, cyclophosphamide, doxorubicin, and prednisone (R-CHP) for the treatment of adult patients who have previously untreated diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS) or high-grade B-cell lymphoma (HGBL) and who have an International Prognostic Index score of 2 or greater. ( 1.1 ) in combination with bendamustine and a rituximab product for the treatment of adult patients with relapsed or refractory DLBCL, NOS, after at least two prior therapies. ( 1.2 ) 1.1 Previously Untreated DLBCL, NOS or HGBL POLIVY in combination with a rituximab product, cyclophosphamide, doxorubicin, and prednisone (R-CHP) is indicated for the treatment of adult patients who have previously untreated diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS) or high-grade B-cell lymphoma (HGBL) and who have an International Prognostic Index score of 2 or greater. 1.2 Relapsed or Refractory DLBCL, NOS POLIVY in combination with bendamustine and a rituximab product is indicated for the treatment of adult patients with relapsed or refractory DLBCL, NOS, after at least two prior therapies.
Mechanism: Polatuzumab vedotin-piiq is a CD79b-directed antibody-drug conjugate with activity against dividing B cells. The small molecule, MMAE, is an anti-mitotic agent covalently attached to the antibody via a cleavable linker. The monoclonal antibody binds to CD79b, a B-cell specific surface protein, which is a component of the B-cell receptor. Upon binding CD79b, polatuzumab vedotin-piiq is internalized, and the linker is cleaved by lysosomal proteases to enable intracellular delivery of MMAE. MMAE binds to microtubules and kills dividing cells by inhibiting cell division and inducing apoptosis.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Apr 19, 2023 Supplement 8 · Efficacy OrphanLabelLetterReview
- Jun 10, 2019 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyAccelerated approvalOrphanLabelReviewLetter
2 products under this application
- POLIVY · POLATUZUMAB VEDOTIN-PIIQ 140MG/VIAL · POWDER, INTRAVENOUS · Prescription
- POLIVY · POLATUZUMAB VEDOTIN-PIIQ 30MG/VIAL · POWDER, INTRAVENOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Polatuzumab Vedotin" as an intervention, any sponsor and status, largest first.
- A Study to Evaluate Surovatamig Combined With R-CHOP in Participants of 18 to < 80 Years of Age With Previously Untreated Large B-cell Lymphoma With IPI Score 2 to 5Pivotal-lookingNot yet recruiting
AstraZenecaAstraZeneca (AZN)
NCT07911553 · 1,200 participants (planned) · Start Dec 22, 2026 · Primary completion Sep 2, 2030
Drug: Surovatamig; Rituximab and 5 more · For: Large B-cell Lymphoma
- An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell LymphomaPivotal-lookingActive, not recruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT06047080 · 1,130 participants · Start Sep 18, 2023 · Primary completion Oct 1, 2027
Drug: Glofitamab; Polatuzumab vedotin and 4 more · For: Large B-Cell Lymphoma
Sites: Anchorage, Alaska; Anaheim, California; Clovis, California · 229 sites in all
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT03274492 · 1,000 participants · Start Nov 16, 2017 · Primary completion Apr 30, 2026
Drug: Polatuzumab Vedotin; Rituximab and 6 more · For: Diffuse Large B-Cell Lymphoma
Sites: Birmingham, Alabama; Daphne, Alabama; Duarte, California · 209 sites in all
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT06890884 · 594 participants (planned) · Start Apr 11, 2025 · Primary completion Dec 13, 2027
Drug: Zilovertamab vedotin; Rituximab and 7 more · For: Lymphoma, Large B-Cell, Diffuse
Sites: Mobile, Alabama; Chandler, Arizona; Glendale, Arizona · 148 sites in all
- A Study Comparing the Efficacy and Safety of Pola-RCHP-X Versus RCHOP-X and Pola-RCHP in Previously Untreated Patients With DLBCLPivotal-lookingNot yet recruiting
The First Affiliated Hospital with Nanjing Medical UniversityAcademic, hospital or other
NCT06516978 · 528 participants (planned) · Start Oct 1, 2024 · Primary completion Oct 1, 2028
Drug: Polatuzumab vedotin; Rituximab and 9 more · For: Diffuse Large B Cell Lymphoma
- A Clinical Trial of MK-1045 With Zilovertamab Vedotin in Participants With Diffuse Large B-cell Lymphoma (MK-1045-010)Pivotal-lookingNot yet recruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT07917754 · 470 participants (planned) · Start Dec 13, 2026 · Primary completion Mar 13, 2037
Drug: MK-1045; Zilovertamab vedotin and 8 more · For: Lymphoma, Large B-Cell, Diffuse; Diffuse Large B-Cell Lymphoma
- A Study to Evaluate the Safety and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in B-Cell Non-Hodgkin LymphomaActive, not recruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT03671018 · 422 participants (planned) · Start Sep 25, 2018 · Primary completion Jan 30, 2024
Drug: Mosunetuzumab (IV); Mosunetuzumab (SC) and 3 more · For: B-cell Non-Hodgkin Lymphoma
Sites: Birmingham, Alabama; Duarte, California; Aurora, Colorado · 29 sites in all
- Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell LymphomaPivotal-lookingRecruiting
SWOG Cancer Research NetworkResearch network
NCT05633615 · 396 participants (planned) · Start Jun 12, 2023 · Primary completion Jun 30, 2030
Drug: Axicabtagene Ciloleucel; Cyclophosphamide and 5 more · For: Diffuse Large B-Cell Lymphoma; Grade 3b Follicular Lymphoma; Primary Mediastinal (Thymic) Large B-Cell Lymphoma and 4 more
Sites: Tucson, Arizona; Fayetteville, Arkansas; Little Rock, Arkansas · 95 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- disease progression2,064
- off label use1,398
- death801
- neutropenia642
- anaemia577
- covid-19549
- febrile neutropenia549
- cytokine release syndrome542
- pyrexia531
- drug ineffective503
- platelet count decreased434
- diffuse large b-cell lymphoma428
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2013 | 2 |
| 2014 | 2 |
| 2015 | 8 |
| 2016 | 35 |
| 2017 | 21 |
| 2018 | 32 |
| 2019 | 253 |
| 2020 | 467 |
| 2021 | 719 |
| 2022 | 1,665 |
| 2023 | 2,266 |
| 2024 | 1,733 |
| 2025 | 1,550 |
| 2026 | 1,449 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Polivy (Polatuzumab Vedotin-Piiq)
2024 spending
$3.8M
Beneficiaries
54
200 claims
Per beneficiary
$70,156
$12,602.91 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $388,010 |
| 2021 | $327,833 |
| 2022 | $958,382 |
| 2023 | $1,291,224 |
| 2024 | $3,788,412 |
Part B: Polivy (Polatuzumab Vedotin-Piiq) · HCPCS J9309
2024 spending
$202M
Beneficiaries
3,042
10,844 claims
Per beneficiary
$66,241
2024 ASP limit $127.02 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $48,096,602 |
| 2021 | $42,318,868 |
| 2022 | $66,197,899 |
| 2023 | $118,943,447 |
| 2024 | $201,503,836 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Preclinical advances in glofitamab combinations: a new frontier for non-Hodgkin lymphoma.
Sam J, Leclercq-Cohen G, Gebhardt S, et al. · Blood 2025 · Clinical Trial, Phase III, Multicenter Study
- Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma.
Tilly H, Morschhauser F, Sehn LH, et al. · N Engl J Med 2022 · Clinical Trial, Phase III, Multicenter Study
- Mosunetuzumab Plus Polatuzumab Vedotin in Transplant-Ineligible Refractory/Relapsed Large B-Cell Lymphoma: Primary Results of the Phase III SUNMO Trial.
Budde LE, Zhang H, Kim WS, et al. · J Clin Oncol 2025 · Clinical Trial, Phase III, Randomized Controlled Trial
- Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
Sehn LH, Herrera AF, Flowers CR, et al. · J Clin Oncol 2020 · Clinical Trial, Phase I, Clinical Trial, Phase II
- Five-Year Outcomes of the POLARIX Study Comparing Pola-R-CHP and R-CHOP in Patients With Diffuse Large B-Cell Lymphoma.
Morschhauser F, Salles G, Sehn LH, et al. · J Clin Oncol 2025 · Multicenter Study, Comparative Study
- Mosunetuzumab with polatuzumab vedotin in relapsed or refractory aggressive large B cell lymphoma: a phase 1b/2 trial.
Budde LE, Olszewski AJ, Assouline S, et al. · Nat Med 2024 · Clinical Trial, Phase I, Clinical Trial, Phase II
Sponsor: Roche (Genentech)
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.